{"id":6806,"date":"2022-06-03T06:07:53","date_gmt":"2022-06-03T06:07:53","guid":{"rendered":"https:\/\/zaratechs.com\/?p=6806"},"modified":"2022-06-03T06:07:53","modified_gmt":"2022-06-03T06:07:53","slug":"hyperlipidemia-drugs-market-trends-scope-size-growth-and-analysis-2022-27","status":"publish","type":"post","link":"https:\/\/zaratechs.com\/hyperlipidemia-drugs-market-trends-scope-size-growth-and-analysis-2022-27\/","title":{"rendered":"Hyperlipidemia Drugs Market Trends, Scope, Size, Growth And Analysis 2022-27"},"content":{"rendered":"\n
According to the latest report by IMARC Group \u201cHyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027<\/strong>\u201c, The global hyperlipidemia drugs market reached a value of US$ 21.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 24.8 Billion by 2027, exhibiting a CAGR of 2.17% during 2022-2027.<\/p>\n\n\n\n Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood. It is a common type of dyslipidemia that can be inherited or result from an unhealthy lifestyle and poor diet. The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs). Hyperlipidemia can be detected by performing a blood test called a lipid panel or lipid profile. Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle. Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver. They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.<\/p>\n\n\n\n